RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-5185
Malaria parasiteP. berghei
Genotype
TaggedGene model (rodent): PBANKA_0309500; Gene model (P.falciparum): PF3D7_0212600; Gene product: secreted protein with altered thrombospondin repeat domain (SPATR)
Name tag: c-myc
Transgene
Transgene not Plasmodium: A fusion of GFP (gfp-mu3) and Luciferase Firefly (LucIAV)
Promoter: Gene model: PBANKA_1133300; Gene model (P.falciparum): PF3D7_1357100; Gene product: elongation factor 1-alpha (eef1a)
3'UTR: Gene model: PBANKA_0719300; Gene product: bifunctional dihydrofolate reductase-thymidylate synthase, putative (dhfr/ts)
Replacement locus: Gene model: PBANKA_0306000; Gene product: 6-cysteine protein (230p)
Phenotype Sporozoite;
Last modified: 28 March 2022, 17:02
  *RMgm-5185
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene tagging, Introduction of a transgene
Reference (PubMed-PMID number) Not published (yet)
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone P. berghei ANKA 676m1cl1 (RMgm-29)
Other information parent line676m1cl1 (RMgm-29) is a reference ANKA mutant line which expresses GFP-luciferase under control of a constitutive promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 16242190).
The mutant parasite was generated by
Name PI/ResearcherCosta DM, Tavares J
Name Group/DepartmentIBMC – Instituto de Biologia Molecular e Celular
Name InstituteUniversidade do Porto
CityPorto
CountryPortugal
Name of the mutant parasite
RMgm numberRMgm-5185
Principal nameSPATR-cmyc
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageNot tested
Gametocyte/GameteNot tested
Fertilization and ookineteNot tested
OocystNot tested
SporozoiteExpression of cmyc-tagged SPATR in sporozoites (as shown by Western analysis)
Liver stageNot tested
Additional remarks phenotype

Mutant/mutation
The mutant expresses a C-terminal 2xcmyc-tagged version of SPATR.

Published in bioRxiv preprint doi: https://doi.org/10.1101/2022.03.06.483110

Protein (function)
The secreted protein with an altered thrombospondin repeat (SPATR) contains two adhesive domains: an atypical thrombospondin type-1 repeat (TSR) and a Type II epidermal growth factor (EGF)-like domain. It is conserved across Plasmodium species and has several orthologues among the Apicomplexa phylum. Although its gene is transcribed in all invasive stages (sporozoites, merozoites and ookinetes), SPATR levels are upregulated in mature sporozoites of both human and rodent infecting Plasmodium species. Moreover, immunolocalization studies detected the protein at the surface of sporozoites of several Plasmodium species, despite the lack of predicted transmembrane domains or a glycosylphosphatidylinositol anchor. Antibodies against the SPATR of P. falciparum also blocked hepatocyte invasion by sporozoites. 

Phenotype
Expression of cmyc-tagged SPATR in sporozoites (as shown by Western analysis)

Mouse polyclonal antibodies against a His-tagged recombinant SPATR detected bands of the approximate predicted size of SPATR (29 or 26 kDa with or without the signal peptide, respectively) in extracts of sporozoites collected from the salivary glands and oocysts, as well as in merozoites. The detection of the protein in WT oocyst-derived sporozoites was unexpected, since previous proteomics studies performed in P. falciparum and P. yoelii had only detected SPATR protein in salivary gland sporozoites, whereas transcripts were present in sporozoites collected from both the oocysts and the salivary  glands, which was suggestive of translational repression. Whether this was due to differences in the parasite species, the technical approaches, or the age of oocyst sporozoites – these were collected from day 19 post-infection onwards in this work, as opposed to days 10–14 in the proteomics studies – remains to be elucidated. Similar band patterns were obtained by Western blot using extracts of sporozoites expressing a c-Myc-tagged SPATR at the C-terminus. Moreover, the tagging of the protein was not detrimental to the parasite as SPATR-myc sporozoites were present in similar numbers compared to controls in oocysts and in the salivary glands and no defects were observed during blood stage growth.

Additional information
 

Other mutants


  Tagged: Mutant parasite with a tagged gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_0309500
Gene Model P. falciparum ortholog PF3D7_0212600
Gene productsecreted protein with altered thrombospondin repeat domain
Gene product: Alternative nameSPATR
Details of the genetic modification
Name of the tagc-myc
Details of taggingC-terminal
Additional remarks: tagging
Commercial source of tag-antibodies
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitetgdhfr
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationTo generate a parasite line expressing a c-Myc-tagged version of SPATR, the WT spatr open reading frame was replaced by a copy of spatr fused with a sequence encoding a 2x c-Myc tag at the C-terminus, by single cross-over homologous recombination. Since the linearization of the transfection vector was restricted to the AdhI restriction site within the spatr gene, modifications were made to pL0033 (BEI Resources) in in order to remove the AdhI restriction site originally present in the plasmid. The pL0033 fragment containing the ampicillin resistance cassette and the AdhI site that resulted from SapI and NcoI digestion was swapped by the fragment containing the kanamycin marker obtained by digestion of pET-28a(+) (Novagen) with the same restriction enzymes, generating pL0033_Kan. The genomic region encompassing 439 bp of the 5’ intergenic region and the open reading frame of spatr excluding the termination codon was then amplified by PCR using primers P24 + P25 and cloned into pL0033_Kan using the NotI and NcoI restriction sites. The 3’ regulatory sequence of spatr (358 bp) amplified with P26 + P27 was inserted downstream of the sequence encoding the 2x c-Myc tag using the FseI/NdeI restriction sites. A point mutation was inserted in the start codon to prevent the translation of the full-length untagged SPATR due to the duplication of part of the locus resulting from the genetic recombination event. To do this, the region containing the first 13 nucleotides of the coding sequence and the entire 5’ intergenic region previously inserted in the construct was swapped for the sequence amplified using primers P24 + P28 and using the NotI/AhdI restriction sites. Parasites were transfected using the AhdI-linearized construct.
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameA fusion of GFP (gfp-mu3) and Luciferase Firefly (LucIAV)
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitegfp (FACS)
Promoter of the selectable markereef1a
Selection (positive) procedureFACS (flowsorting)
Selection (negative) procedureNo
Additional remarks genetic modificationThe GFP-Luciferase gene (1 copy) has been inserted into the 230p locus (PB000214.00.0) by double cross-over integration.
Additional remarks selection procedureThis reporter mutant expressing GFP-Luciferase does not contain a drug-selectable marker. This mutant has been selected by FACS sorting after transfection based on GFP fluorescence.
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1133300
Gene Model P. falciparum ortholog PF3D7_1357100
Gene productelongation factor 1-alpha
Gene product: Alternative nameeef1a
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0719300
Gene productbifunctional dihydrofolate reductase-thymidylate synthase, putative
Gene product: Alternative namedhfr/ts
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0306000
Gene product6-cysteine protein
Gene product: Alternative name230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4